Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, Calif., (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company ...

(RTTNews) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin, in individuals ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

Exubera, a rapid-acting insulin in powder form ... are also under investigation. In humans, inhaled regular insulin is more rapidly absorbed than insulin from the subcutaneous injection site.

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Inhaled insulin is a new option for type 2 diabetic patients with poor glycemic control on oral monotherapy. A rapid-acting inhaled insulin (Exubera) was approved recently for treatment of type 1 ...

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and ...

Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market ...

MESA, AZ (AZFamily) — Inhaled insulin is now considered “standard of care” for diabetics, according to updated guidelines from the American Diabetes Association. Inhaled insulin works faster ...

This is the first and only non- injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.